# US 2025/0144116 A1 · Certain n-(1-cyan0-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating hidradenitis suppurativa

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0144116 A1
- Document ID: US20250144116A1
- Status: Published application
- Kind: A1
- Application number: 18/838,823
- Filed: 2023-02-16
- Published: 2025-05-08
- Earliest claimed: 2022-02-16
- Assignees: Insmed Incorporated
- Applicants: Insmed Incorporated
- Inventors: Ariel TEPER; Andrea MAES; Marcela VERGARA; Christina RAMIREZ
- Web page: https://patentgrep.com/patent/US20250144116A1

## CPC

- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 17/00: Drugs for dermatological disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure relates to methods for treating hidradenritis suppurativa with a composition comprising an effective amount of a N-(1-cyano-2-phenylethyl)-1, 4-oxazepane-2-carboxamide DPP1 inhibitor compound of Formula (1) or a pharmaceutically acceptable salt thereof. In one embodiment, the compound of Formula (I) is (2S)—N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1, 3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide (brensocatib).

## Claims

### Claim 1

A method of treating hidradenitis suppurativa (HS) in a subject in need thereof, comprising: administering to the subject for an administration period, a pharmaceutical composition comprising an effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof,
wherein,
R1 is
R2 is hydrogen, F, Cl, Br, OSO2C1-3alkyl, or C1-3alkyl;
R3 is hydrogen, F, Cl, Br, CN, CF3, SO2C1-3alkyl, CONH2 or SO2NR4R5,
wherein R4 and R5 together with the nitrogen atom to which they are attached form an azetidine, pyrrolidine or piperidine ring; or
X is O, S or CF2;
Y is O or S;
Q is CH or N;
R6 is C1-3alkyl, wherein said C1-3alkyl is optionally substituted by 1, 2 or 3 F and optionally by one substituent selected from the group consisting of OH, OC1-3alkyl, N(C1-3alkyl)2, cyclopropyl, and tetrahydropyran; and
R7 is hydrogen, F, Cl or CH3,
thereby treating hidradenitis suppurativa in the subject.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject has not been treated with an anti-TNFα agent previously.

### Claim 3 (depends on 1, 2)

The method of claim 1 or 2, wherein the HS is Hurley Stage I HS, Hurley Stage II HS or Hurley Stage III HS.

### Claim 4 (depends on 3)

The method of claim 3, wherein the HS is Hurley Stage I HS.

### Claim 5 (depends on 3)

The method of claim 3, wherein the HS is Hurley Stage II HS.

### Claim 6 (depends on 3)

The method of claim 3, wherein the HS is Hurley Stage III HS.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the compound of Formula (I) inhibits DPP1.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the HS is refractory HS.

### Claim 9 (depends on 8)

The method of claim 8, wherein the HS was not responsive to a prior, different HS treatment.

### Claim 10 (depends on 9)

The method of claim 9, wherein the prior, different HS treatment comprises administration of a systemic antibiotic.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, further comprising diminishing the severity of, or eliminating one or more symptoms of HS of the subject, during or subsequent to the administration period, compared to the one or more symptoms prior to the administration period.

### Claim 12 (depends on 11)

The method of claim 11, wherein the one or more symptoms of HS are: (a) one or more skin lesions; (b) one or more skin abscesses; (c) one or more fistulas; (d) one or more sinus tracts; (e) skin scarring; (f) anxiety; (g) depression; (h) suicidal thoughts; or (i) any combinations thereof.

### Claim 13 (depends on 12)

The method of claim 12, wherein prior to the administration period, the one or more skin lesions, one or more skin abscesses, one or more fistulas, one or more sinus tracts, or a combination thereof are painful, inflamed, swollen, or a combination thereof.

### Claim 14 (depends on 12, 13)

The method of claim 12 or claim 13, wherein the one or more skin lesions, one or more skin abscesses, one or more fistulas, one or more sinus tracts, or a combination thereof are present on an armpit, groin, buttocks, or a combination thereof, of the subject.

### Claim 15 (depends on 12, 13, 14)

The method of any one of claims 12-14, wherein the one or more skin lesions, one or more skin abscesses, one or more fistulas, one or more sinus tracts, or a combination thereof are associated with hair follicles.

### Claim 16 (depends on 12, 13, 14, 15)

The method of any one of claims 12-15, wherein the one or more skin lesions are one or more skin nodules.

### Claim 17 (depends on 16)

The method of claim 16, wherein the one or more skin nodules are one or more inflammatory skin nodules.

### Claim 18 (depends on 12, 13, 14, 15, 16, 17)

The method of any one of claims 12-17, wherein the one or more skin lesions are interconnected by one or more sinus tracts.

### Claim 19 (depends on 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 12-18, wherein the one or more skin lesions are one or more fistulas.

### Claim 20 (depends on 19)

The method of claim 19, wherein the one or more fistulas comprise one or more draining fistulas.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 1-20, further comprising reducing a skin abscess and inflammatory skin nodule count (AN count) of the subject during or subsequent to the administration period, as compared to an AN count of the subject prior to the administration period.

### Claim 22 (depends on 21)

The method of claim 21, wherein the AN count of the subject prior to the administration period is ≥3.

### Claim 23 (depends on 21, 22)

The method of claim 21 or 22, wherein the AN count of the subject during or subsequent to the administration period is at least 10% less than the AN count of the subject prior to the administration period.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, comprising reducing an occurrence of HS flares in the subject during or subsequent to the administration period, as compared to an occurrence of HS flares in the subject prior to the administration period.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The method of any one of claims 1-24, comprising reducing or maintaining a fistula count of the subject during or subsequent to the administration period, as compared to a fistula count of the subject prior to the administration period.

### Claim 26 (depends on 25)

The method of claim 25, wherein the fistula count of the subject prior to the administration period is ≤20.

### Claim 27 (depends on 25, 26)

The method of claim 25 or 26, wherein the fistula count is a draining fistula count.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The method of any one of claims 1-27, wherein the subject achieves a Hidradenitis Suppurative Clinical Response 50 (HiSCR50) during or subsequent to the administration period, wherein the HiSCR50 is at least a 50% reduction in total AN count, with no increase in skin abscess count, and no increase in draining fistula count, as compared to a total AN count, a skin abscess count, and a draining fistula count of the subject, respectively, prior to the administration period.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The method of any one of claims 1-28, wherein the subject achieves a Hidrahenitis Suppurative Clinical Response 75 (HiSCR75) during or subsequent to the administration period, wherein the HiSCR75 is at least a 75% reduction in total AN count, with no increase in skin abscess count, and no increase in draining fistula count, as compared to a total AN count, a skin abscess count, and a draining fistula count of the subject, respectively, prior to the administration period.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The method of any one of claims 1-29, wherein the subject achieves a Hidrahenitis Suppurative Clinical Response 90 (HiSCR90) during or subsequent to the administration period, wherein the HiSCR90 is at least a 90% reduction in total AN count, with no increase in skin abscess count, and no increase in draining fistula count, as compared to a total AN count, a skin abscess count, and a draining fistula count of the subject, respectively, prior to the administration period.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)

The method of any one of claims 1-30, wherein the subject achieves a modified Hidradenitis Suppurativa Clinical Response (mHiSCR) during or subsequent to the administration period, wherein the mHiSCR is a ≥50% reduction in total number of inflammatory nodules, abscesses, and draining fistulas and a ≥50% reduction in total number of draining fistulas, as compared to a total number of inflammatory nodules, abscesses, and draining fistulas and a total number of draining fistulas of the subject, respectively, prior to the administration period.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 1-31, comprising reducing a Patient's Global Assessment of Skin Pain (PGA-SP) score of the subject during or subsequent to the administration period, as compared to a PGA-SP score of the subject prior to the administration period.

### Claim 33 (depends on 32)

The method of claim 32, wherein the PGA-SP score of the subject prior to the administration period is ≥3.

### Claim 34 (depends on 32, 33)

The method of claim 32 or 33, wherein the PGA-SP score of the subject during or subsequent to the administration period is at least about 10% less than the PGA-SP score of the subject prior to the administration period.

### Claim 35 (depends on 32, 33, 34)

The method of any one of claims 32-34, wherein the PGA-SP score of the subject during or subsequent to the administration period is 3 or less.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 1-35, comprising reducing an International hidradenitis suppurativa severity (IHS4) score of the subject during or subsequent to the administration period, as compared to an IHS4 score of the subject prior to the administration period.

### Claim 37 (depends on 36)

The method of claim 36, wherein the IHS4 score of the subject during or subsequent to the administration period is at least about 10% less than the IHS4 score of the subject prior to the administration period.

### Claim 38 (depends on 36, 37)

The method of claim 36 or 37, wherein the IHS4 score of the subject during or subsequent to the administration period is reduced from an HS Hurley Stage III score to an HS Hurley Stage II score.

### Claim 39 (depends on 36, 37)

The method of claim 36 or 37, wherein the IHS4 score of the subject during or subsequent to the administration period is reduced from an HS Hurley Stage III score to an HS Hurley Stage I score.

### Claim 40 (depends on 36, 37)

The method of claim 36 or 37, wherein the IHS4 score of the subject during or subsequent to the administration period is reduced from an HS Hurley Stage II score to an HS Hurley Stage I score.

### Claim 41 (depends on 36, 37, 38, 39, 40)

The method of any one of claims 36-40, wherein the IHS4 score of the subject is ≥4 prior to the administration period.

### Claim 42 (depends on 41)

The method of claim 41, wherein the IHS4 score of the subject is 10 prior to the administration period.

### Claim 43 (depends on 41)

The method of claim 41, wherein the IHS4 score of the subject is 11 prior to the administration period.

### Claim 44 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The method of any one of claims 1-43, comprising reducing a Hidradenitis Suppurativa Quality of Life (HiSQOL) score of the subject during or subsequent to the administration period, as compared to a HiSQOL score of the subject prior to the administration period.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The method of any one of claims 1-44, comprising reducing a Hidradenitis Suppurativa-Investigator's Global Assessment (HS-IGA) score of the subject during or subsequent to the administration period, as compared to an HS-IGA score of the subject prior to the administration period.

### Claim 46 (depends on 45)

The method of claim 45, wherein the HS-IGA score of the subject is reduced ≥2 points during or subsequent to the administration period.

### Claim 47 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The method of any one of claims 1-46, comprising reducing a Dermatology Life Quality Index (DLQI) score of the subject during or subsequent to the administration period, as compared to a DLQI score of the subject prior to the administration period.

### Claim 48 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The method of any one of claims 1-47, comprising improving the Hurley Stage of the HS of the subject during or subsequent to the administration period, as compared to the Hurley Stage of the HS of the subject prior to the administration period.

### Claim 49 (depends on 48)

The method of claim 48, wherein the improving the Hurley Stage of the HS of the subject comprises reducing the severity of the HS of the subject from Hurley Stage III to Hurley Stage II.

### Claim 50 (depends on 48)

The method of claim 48, wherein the improving the Hurley Stage of the HS of the subject comprises reducing the severity of the HS of the subject from Hurley Stage III to Hurley Stage I.

### Claim 51 (depends on 48)

The method of claim 48, wherein the improving the Hurley Stage of the HS of the subject comprises reducing the severity of the HS of the subject from Hurley Stage II to Hurley Stage I.

### Claim 52 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51)

The method of any one of claims 1-51, comprising reducing a HS-Related Patient Global Assessment (HS-related PtGA) score of the subject during or subsequent to the administration period, as compared to an HS-related PtGA score of the subject prior to the administration period.

### Claim 53 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The method of any one of claims 1-52, wherein the number of neutrophils in a biological sample obtained from the subject prior to the administration period is greater than the number of neutrophils in a counterpart biological sample obtained from a control subject who does not have HS.

### Claim 54 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53)

The method of any one of claims 1-53, wherein the number of neutrophils in a biological sample obtained from the subject during or subsequent to the administration period is less than: (a) the number of neutrophils in a counterpart biological sample obtained from the subject prior to the administration period, and/or (b) the number of neutrophils in a counterpart biological sample obtained from a control subject, wherein the control subject has HS and is not administered the pharmaceutical composition.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54)

The method of any one of claims 1-54, wherein the level of SA100A7 in a biological sample obtained from the subject prior to the administration period is greater than the level of SA100A7 in a counterpart biological sample obtained from a control subject who does not have HS.

### Claim 56 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

The method of any one of claims 1-55, wherein the level of SA100A7 in a biological sample obtained from the subject during or subsequent to the administration period is less than: (a) the level of SA100A7 in a counterpart biological sample obtained from the subject prior to the administration period, and/or (b) the level of SA100A7 in a counterpart biological sample obtained from a control subject, wherein the control subject has HS and is not administered the pharmaceutical composition.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56)

The method of any one of claims 1-56, wherein the level of myeloperoxidase (MPO) in a biological sample obtained from the subject prior to the administration period is greater than the level of MPO in a counterpart biological sample obtained from a control subject who does not have HS.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57)

The method of any one of claims 1-57, wherein the level of MPO in a biological sample obtained from the subject during or subsequent to the administration period is less than: (a) the level of MPO in a counterpart biological sample obtained from the subject prior to the administration period, and/or (b) the level of MPO in a counterpart biological sample obtained from a control subject, wherein the control subject has HS and is not administered the pharmaceutical composition.

### Claim 59 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The method of any one of claims 1-58, wherein the activity of peptidylarginine deiminase 4 (PAD4) in a biological sample obtained from the subject prior to the administration period is greater than the activity of peptidylarginine deiminase 4 (PAD4) in a counterpart biological sample obtained from a control subject who does not have HS.

### Claim 60 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59)

The method of any one of claims 1-59, wherein the level of PAD4 in a biological sample obtained from the subject during or subsequent to the administration period is less than: (a) the level of PAD4 in a counterpart biological sample obtained from the subject prior to the administration period, and/or (b) the level of PAD4 in a counterpart biological sample obtained from a control subject, wherein the control subject has HS and is not administered the pharmaceutical composition.

### Claim 61 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60)

The method of any one of claims 1-60, wherein the level of a cytokine and/or a lipid mediator in a biological sample obtained from the subject prior to the administration period is greater than the level of the cytokine and/or the lipid mediator in a counterpart biological sample obtained from a control subject who does not have HS.

### Claim 62 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61)

The method of any one of claims 1-61, wherein the level of a cytokine and/or lipid mediator in a biological sample obtained from the subject during or subsequent to the administration period is less than: (a) the level of the cytokine and/or lipid mediator in a counterpart biological sample obtained from the subject prior to the administration period, and/or (b) the level of the cytokine and/or lipid mediator in a counterpart biological sample obtained from a control subject, wherein the control subject has HS and is not administered the pharmaceutical composition.

### Claim 63 (depends on 61, 62)

The method of claim 61 or 62, wherein the cytokine is a chemokine.

### Claim 64 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any one of claims 1-63, wherein the level of C-reactive protein (CRP) in a biological sample obtained from the subject prior to the administration period is greater than the level of C-reactive protein (CRP) in a counterpart biological sample obtained from a control subject who does not have HS.

### Claim 65 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

The method of any one of claims 1-64, wherein the level of CRP in a biological sample obtained from the subject during or subsequent to the administration period is less than: (a) the level of CRP in a counterpart biological sample obtained from the subject prior to the administration period, and/or (b) the level of CRP in a counterpart biological sample obtained from a control subject, wherein the control subject has HS and is not administered the pharmaceutical composition.

### Claim 66 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65)

The method of any one of claims 1-65, wherein prior to the administration period, the level of DPP1 in a biological sample obtained from the subject is in the range of from about 1 ng/mL to about 100 ng/mL.

### Claim 67 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66)

The method of any one of claims 1-66, wherein prior to the administration period, the level of neutrophil extracellular traps (NETs) in a biological sample obtained from the subject is in the range of from about 1 ng/mL to about 1000 ng/mL.

### Claim 68 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67)

The method of any one of claims 1-67, wherein prior to the administration period, the level of a neutrophil serine protease (NSP) in a biological sample obtained from the subject is in the range of from about 1 ng/mL to about 1000 ng/mL.

### Claim 69 (depends on 68)

The method of claim 68, wherein the NSP is neutrophil elastase (NE), proteinase 3 (PR3), cathepsin G (CatG), neutrophil serine protease 4 (NSP4), or any combination thereof.

### Claim 70 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69)

The method of any one of claims 1-69, wherein the activity of DPP1 in a biological sample obtained from the subject during or subsequent to the administration period is less than: (a) the activity of DPP1 in a counterpart biological sample obtained from the subject prior to the administration period, and/or (b) the activity of DPP1 in a counterpart biological sample obtained from a control subject, wherein the control subject has HS and is not administered the pharmaceutical composition.

### Claim 71 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

The method of any one of claims 1-70, wherein the activity of a neutrophil serine protease (NSP) in a biological sample obtained from the subject during or subsequent to the administration period is less than: (a) the activity of the NSP in a counterpart biological sample obtained from the subject prior to the administration period, and/or (b) the activity of the NSP in a counterpart biological sample obtained from a control subject, wherein the control subject has HS and is not administered the pharmaceutical composition.

### Claim 72 (depends on 71)

The method of claim 71, wherein the NSP is selected from the group consisting of neutrophil elastase (NE), proteinase 3 (PR3), cathepsin G (CatG), and neutrophil serine protease 4 (NSP4).

### Claim 73 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

The method of any one of claims 1-72, wherein the level of neutrophil extracellular traps (NETs) in a biological sample obtained from the subject during or subsequent to the administration period is less than: (a) the level of NETs in a counterpart biological sample obtained from the subject prior to the administration period, and/or (b) the level of NETs in a counterpart biological sample obtained from a control subject, wherein the control subject has HS and is not administered the pharmaceutical composition.

### Claim 74 (depends on 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

The method of any one of claims 53-73, wherein the biological sample is skin tissue, blood, serum, or a combination thereof.

### Claim 75 (depends on 74)

The method of claim 74, wherein the biological sample is skin tissue.

### Claim 76 (depends on 74, 75)

The method of claim 74 or claim 75, wherein the skin tissue comprises tissue derived from one or more skin lesions, one or more skin abscesses, one or more fistulas, one or more sinus tracts, one or more skin scars, one or more sinus tracts, or a combination thereof.

### Claim 77 (depends on 76)

The method of claim 76, wherein the skin tissue comprises tissue derived from one or more fistulas.

### Claim 78 (depends on 77)

The method of claim 77, wherein the one or more fistulas comprises one or more draining fistulas.

### Claim 79 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78)

The method of any one of claims 1-78, further comprising administering a secondary therapy to the subject.

### Claim 80 (depends on 79)

The method of claim 79, wherein the secondary therapy is administered: (a) prior to the administration period, (b) during or subsequent to the administration period, or (c) concurrently with administering the pharmaceutical composition.

### Claim 81 (depends on 79, 80)

The method of claim 79 or claim 80, wherein the secondary therapy comprises one or more of the following: an antibiotic, a steroid, a biologic, a hormone, a retinoid, an anti-inflammatory drug, a surgical intervention, or any combination thereof.

### Claim 82 (depends on 81)

The method of claim 81, wherein the antibiotic is applied topically.

### Claim 83 (depends on 81, 82)

The method of claim 81 or claim 82, wherein the antibiotic is doxycycline, minocycline, clindamycin, rifampin, or any combination thereof.

### Claim 84 (depends on 81)

The method of claim 81, wherein the steroid is triamcinolone.

### Claim 85 (depends on 81)

The method of claim 81, wherein the biologic is an anti-TNF-alpha antibody.

### Claim 86 (depends on 85)

The method of claim 85, wherein the anti-TNF-alpha antibody is adalimumab, infliximab, or a combination thereof.

### Claim 87 (depends on 81)

The method of claim 81, wherein the biologic is an IL-17 inhibitor, an IL-12 inhibitor, an IL-23 inhibitor, a JAK-1 inhibitor, or any combination thereof.

### Claim 88 (depends on 81)

The method of claim 81, wherein the hormone is estrogen.

### Claim 89 (depends on 81)

The method of claim 81, wherein the anti-inflammatory drug is aspirin, ibuprofen, naproxen, celecoxib, indomethacin, ketorolac, diclofenac, ketoprofen, or any combination thereof.

### Claim 90 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The method of any one of claims 1-89, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is the S,S diastereomer:

### Claim 91 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The method of any one of claims 1-89, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is the S,R diastereomer:

### Claim 92 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The method of any one of claims 1-89, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is the R,S diastereomer:

### Claim 93 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The method of any one of claims 1-89, wherein the compound of Formula (I), or a pharmaceutically acceptable salt thereof, is the R,R diastereomer:

### Claim 94 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93)

The method of any one of claims 1-93, wherein,
R1 is
X is O, S or CF2;
Y is O or S;
Q is CH or N;
R6 is C1-3alkyl, wherein said C1-3alkyl is optionally substituted by 1, 2 or 3 F and optionally by one substituent selected from the group consisting of OH, OC1-3alkyl, N(C1-3alkyl)2, cyclopropyl, and tetrahydropyran; and
R7 is hydrogen, F, Cl or CH3.

### Claim 95 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94)

The method of any one of claims 1-94, wherein,
R1 is
X is O, S or CF2;
Y is O or S;
R6 is C1-3alkyl, wherein said C1-3alkyl is optionally substituted by 1, 2 or 3 F and optionally by one substituent selected from the group consisting of OH, OC1-3alkyl, N(C1-3alkyl)2, cyclopropyl, and tetrahydropyran; and
R7 is hydrogen, F, Cl or CH3.

### Claim 96 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

The method of any one of claims 1-95, wherein, R1 is

### Claim 97 (depends on 96)

The method of claim 96, wherein X is O; R6 is C1-3alkyl; and R7 is hydrogen.

### Claim 98 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The method of any one of claims 1-96, wherein,
R1 is
X is O;
R6 is C1-3alkyl, wherein said C1-3alkyl is optionally substituted by 1, 2 or 3 F; and
R7 is hydrogen.

### Claim 99 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96)

The method of any one of claims 1-96, wherein,
R1 is
X is O;
R6 is C1-3alkyl; and
R7 is hydrogen.

### Claim 100 (depends on 90)

The method of claim 90, wherein the compound of Formula (I) is (2S)—N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-y-l)phenyl]ethyl}-1,4-oxazepane-2-carboxamide (brensocatib)
or a pharmaceutically acceptable salt thereof.

### Claim 101 (depends on 90)

The method of claim 90, wherein the compound of Formula (I) is (2S)—N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-y-l)phenyl]ethyl}-1,4-oxazepane-2-carboxamide (brensocatib)

### Claim 102 (depends on 90)

The method of claim 90, wherein the compound of Formula (I) is a hydrate of (2S)—N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-y-l)phenyl]ethyl}-1,4-oxazepane-2-carboxamide (brensocatib)
or a pharmaceutically acceptable salt thereof.

### Claim 103 (depends on 90)

The method of claim 90, wherein the compound of Formula (I) is selected from the group consisting of
(2S)—N-[(1S)-1-Cyano-2-(4′-cyanobiphenyl-4-yl)ethyl]-1,4-oxazepane-2-carboxamide;
(2S)—N-{(1S)-1-Cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;
(2S)—N-{(1S)-1-Cyano-2-[4-(3,7-dimethyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;
4′-[(2S)-2-Cyano-2-{[(2S)-1,4-oxazepan-2-ylcarbonyl]amino}ethyl]biphenyl-3-yl methanesulfonate;
(2S)—N-{(1S)-1-Cyano-2-[4-(3-methyl-1,2-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;
(2S)—N-{(1S)-1-Cyano-2-[4′-(trifluoromethyl)biphenyl-4-yl]ethyl}-1,4-oxazepane-2-carboxamide;
(2S)—N-[(1S)-1-Cyano-2-(3′,4′-difluorobiphenyl-4-yl)ethyl]-1,4-oxazepane-2-carboxamide;
(2S)—N-{(15)-1-Cyano-2-[4-(6-cyanopyridin-3-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;
(2S)—N-{(1S)-1-Cyano-2-[4-(4-methyl-3-oxo-3,4-dihydro-2H-1,4-benzothiazin-6-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;
(2S)—N-{(1S)-1-Cyano-2-[4-(3-ethyl-7-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;
(2S)—N-[(1S)-1-Cyano-2-{4-[3-(2-hydroxy-2-methylpropyl)-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;
(2S)—N-[(1S)-1-Cyano-2-{4-[3-(2,2-difluoroethyl)-7-fluoro-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;
(2S)—N-[(1S)-1-Cyano-2-(4-{3-[2-(dimethylamino)ethyl]-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl}phenyl)ethyl]-1,4-oxazepane-2-carboxamide;
(2S)—N-{(1S)-1-Cyano-2-[4-(3,3-difluoro-1-methyl-2-oxo-2,3-dihydro-1H-indol-6-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;
(2S)—N-{(15)-1-Cyano-2-[4-(7-fluoro-3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;
(2S)—N-{(15)-1-Cyano-2-[4-(3-ethyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;
(2S)—N-[(1S)-1-Cyano-2-{4-[3-(cyclopropylmethyl)-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;
(2S)—N-[(1S)-1-Cyano-2-{4-[3-(2-methoxyethyl)-2-oxo-2,3-dihydro-1,3-benzothiazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;
(2S)—N-[(1S)-1-Cyano-2-{4-[2-oxo-3-(propan-2-yl)-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;
(2S)—N-{(15)-1-Cyano-2-[4-(4-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;
(2S)—N-[(1S)-1-Cyano-2-{4-[3-(2-methoxyethyl)-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;
(2S)—N-{(1S)-1-Cyano-2-[4-(5-cyanothiophen-2-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;
(2S)—N-[(1S)-2-(4′-Carbamoyl-3′-fluorobiphenyl-4-yl)-1-cyanoethyl]-1,4-oxazepane-2-carboxamide;
(2S)—N-{(1S)-1-Cyano-2-[4-(1-methyl-2-oxo-1,2-dihydroquinolin-7-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;
(2S)—N-[(1S)-1-Cyano-2-{4-[2-oxo-3-(tetrahydro-2H-pyran-4-ylmethyl)-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;
(2S)—N-{(1S)-2-[4-(7-Chloro-3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]-1-cyanoethyl}-1,4-oxazepane-2-carboxamide;
(2S)—N-[(1S)-1-Cyano-2-{4-[3-(2,2-difluoroethyl)-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;
(2S)—N-[(1S)-1-Cyano-2-{4-[2-oxo-3-(2,2,2-trifluoroethyl)-2,3-dihydro-1,3-benzoxazol-5-yl]phenyl}ethyl]-1,4-oxazepane-2-carboxamide;
(2S)—N-{(1S)-1-Cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzothiazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide;
(2S)—N-{(1S)-1-Cyano-2-[4′-(methylsulfonyl)biphenyl-4-yl]ethyl}-1,4-oxazepane-2-carboxamide;
(2S)—N-{(1S)-2-[4′-(Azetidin-1-ylsulfonyl)biphenyl-4-yl]-1-cyanoethyl}-1,4-oxazepane-2-carboxamide;
(2S)—N-[(1S)-1-Cyano-2-(4′-fluorobiphenyl-4-yl)ethyl]-1,4-oxazepane-2-carboxamide;
(2S)—N-{(1S)-2-[4-(1,3-Benzothiazol-5-yl)phenyl]-1-cyanoethyl}-1,4-oxazepane-2-carboxamide;
(2S)—N-[(1S)-1-Cyano-2-(4′-cyanobiphenyl-4-yl)ethyl]-1,4-oxazepane-2-carboxamide;
and pharmaceutically acceptable salts thereof.

### Claim 104 (depends on 91)

The method of claim 91, wherein the compound of Formula (I) is (2S)—N-{(1R)-1-Cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide:
or a pharmaceutically acceptable salt thereof.

### Claim 105 (depends on 104)

The method of claim 104, wherein the compound of Formula (I) is (2S)—N-{(1R)-1-Cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide:

### Claim 106 (depends on 92)

The method of claim 92, wherein the compound of Formula (I) is (2R)—N-{(1S)-1-Cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide:
or a pharmaceutically acceptable salt thereof.

### Claim 107 (depends on 106)

The method of claim 106, wherein the compound of Formula (I) is (2R)—N-{(1S)-1-Cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide:

### Claim 108 (depends on 93)

The method of claim 93, wherein the compound of Formula (I) is (2R)—N-{(1R)-1-Cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide:
or a pharmaceutically acceptable salt thereof.

### Claim 109 (depends on 108)

The method of claim 108, wherein the compound of Formula (I) is (2R)—N-{(1R)-1-Cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide:

### Claim 110 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The method of any one of claims 1-89, wherein the pharmaceutical composition comprises a mixture of an S,S diastereomer of a compound of Formula (I) and an S,R diastereomer of a compound of Formula (I).

### Claim 111 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The method of any one of claims 1-89, wherein the pharmaceutical composition comprises a mixture of an S,S diastereomer of a compound of Formula (I) and an R,S diastereomer of a compound of Formula (I).

### Claim 112 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The method of any one of claims 1-89, wherein the pharmaceutical composition comprises a mixture of an S,S diastereomer of a compound of Formula (I) and an R,R diastereomer of a compound of Formula (I).

### Claim 113 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The method of any one of claims 1-89, wherein the pharmaceutical composition comprises a mixture of brensocatib, or a pharmaceutically acceptable salt thereof and (2S)—N-{(1R)-1-Cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide:
or a pharmaceutically acceptable salt thereof.

### Claim 114 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The method of any one of claims 1-89, wherein the pharmaceutical composition comprises a mixture of brensocatib, or a pharmaceutically acceptable salt thereof and (2R)—N-{(1S)-1-Cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide:
or a pharmaceutically acceptable salt thereof.

### Claim 115 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89)

The method of any one of claims 1-89, wherein the pharmaceutical composition comprises a mixture of brensocatib, or a pharmaceutically acceptable salt thereof and (2R)—N—{(1R)-1-Cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide:
or a pharmaceutically acceptable salt thereof.

### Claim 116 (depends on 1, 115)

The method of any one of claims 1-115, wherein the pharmaceutical composition is administered once-a-day, twice-a-day, or every other day during the administration period.

### Claim 117 (depends on 1, 116)

The method of any one of claims 1-116, wherein the pharmaceutical composition is administered once-a-day during the administration period.

### Claim 118 (depends on 1, 117)

The method of any one of claims 1-117, wherein the pharmaceutical composition is administered orally during the administration period.

### Claim 119 (depends on 1, 117)

The method of any one of claims 1-117, wherein the pharmaceutical composition is administered parenterally, enterally, or through a nasogastric tube during the administration period.

### Claim 120 (depends on 1, 119)

The method of any one of claims 1-119, wherein the compound of Formula (I) is present in the pharmaceutical composition from about 1 mg to about 100 mg.

### Claim 121 (depends on 120)

The method of claim 120, wherein the compound of Formula (I) is present in the pharmaceutical composition at about 10 mg.

### Claim 122 (depends on 120)

The method of claim 120, wherein the compound of Formula (I) is present in the pharmaceutical composition at about 25 mg.

### Claim 123 (depends on 120)

The method of claim 120, wherein the compound of Formula (I) is present in the pharmaceutical composition at about 40 mg.

### Claim 124 (depends on 120)

The method of claim 120, wherein the compound of Formula (I) is present in the pharmaceutical composition at about 5 mg to about 50 mg.

### Claim 125 (depends on 120)

The method of claim 120, wherein the compound of Formula (I) is present in the pharmaceutical composition at about 10 mg to about 40 mg.

### Claim 126 (depends on 120)

The method of claim 120, wherein the compound of Formula (I) is present in the pharmaceutical composition at about 10 mg to about 25 mg.

### Claim 127 (depends on 1, 126)

The method of any one of claims 1-126, wherein the administration period is about 30 days, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 12 months, about 18 months, about 24 months or about 30 months.

### Claim 128 (depends on 1, 126)

The method of any one of claims 1-126, wherein the administration period is at least about 30 days, at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 18 months, at least about 24 months or at least about 30 months.

### Claim 129 (depends on 1, 126)

The method of any one of claims 1-126, wherein the administration period is about 30 days, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 7 months, about 8 months, about 9 months, about 10 months, about 11 months, about 12 months, about 18 months, about 24 months, about 30 months, about 36 months, about 4 years, about 5 years, about 10 years, about 15 years or about 20 years.

### Claim 130 (depends on 1, 126)

The method of any one of claims 1-126, wherein the administration period is at least about 30 days, at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, at least about 6 months, at least about 7 months, at least about 8 months, at least about 9 months, at least about 10 months, at least about 11 months, at least about 12 months, at least about 18 months, at least about 24 months, at least about 30 months, at least about 36 months, at least about 4 years, at least about 5 years, at least about 10 years, at least about 15 years or at least about 20 years.

### Claim 131 (depends on 1, 126)

The method of any one of claims 1-126, wherein the administration period is about 6 months.

### Claim 132 (depends on 1, 126)

The method of any one of claims 1-126, wherein the administration period is about 12 months.

### Claim 133 (depends on 1, 126)

The method of any one of claims 1-126, wherein the administration period is from about 6 months to about 36 months.

### Claim 134 (depends on 1, 126)

The method of any one of claims 1-126, wherein the administration period is from about 12 months to about 36 months.

### Claim 135 (depends on 1, 126)

The method of any one of claims 1-126, wherein the administration period is from about 18 months to about 36 months.

### Claim 136 (depends on 1, 126)

The method of any one of claims 1-126, wherein the administration period is from about 1 year to about 50 years.

### Claim 137 (depends on 1, 126)

The method of any one of claims 1-126, wherein the administration period is from about 1 year to about 40 years.

### Claim 138 (depends on 1, 126)

The method of any one of claims 1-126, wherein the administration period is from about 1 year to about 30 years.

### Claim 139 (depends on 1, 126)

The method of any one of claims 1-126, wherein the administration period is from about 1 year to about 25 years.

### Claim 140 (depends on 1, 126)

The method of any one of claims 1-126, wherein the administration period is from about 1 year to about 20 years.

### Claim 141 (depends on 1, 126)

The method of any one of claims 1-126, wherein the administration period is from about 1 year to about 15 years.

### Claim 142 (depends on 1, 126)

The method of any one of claims 1-126, wherein the administration period is from about 1 year to about 10 years.

### Claim 143 (depends on 1, 126)

The method of any one of claims 1-126, wherein the administration period is from about 1 year to about 5 years.

### Claim 144 (depends on 1, 126)

The method of any one of claims 1-126, wherein the administration period is from about 1 year to about 3 years.

### Claim 145 (depends on 1, 126)

The method of any one of claims 1-126, wherein the administration period is from about 1 year to about 2 years.

### Claim 146 (depends on 1, 126)

The method of any one of claims 1-126, wherein the administration period is from about 2 years to about 15 years.

### Claim 147 (depends on 1, 126)

The method of any one of claims 1-126, wherein the administration period is from about 2 years to about 10 years.

### Claim 148 (depends on 1, 126)

The method of any one of claims 1-126, wherein the administration period is from about 2 years to about 8 years.

### Claim 149 (depends on 1, 126)

The method of any one of claims 1-126, wherein the administration period is from about 2 years to about 5 years.

### Claim 150 (depends on 1, 126)

The method of any one of claims 1-126, wherein the administration period is from about 2 years to about 4 years.

### Claim 151 (depends on 1, 150)

The method of any one of claims 1-150, wherein the subject is at a risk of developing HS.

### Claim 152 (depends on 151)

The method of claim 151, wherein the subject at a risk of developing HS is or was repeatedly exposed to tobacco smoke; has a family history of HS; or a combination thereof.

### Claim 153 (depends on 1, 152)

The method of any one of claims 1-152, wherein the HS is associated with the presence or development of one or more of: acne, arthritis, diabetes, metabolic syndrome, inflammatory bowel disease, obesity, or any combination thereof.

### Claim 154 (depends on 11, 153)

The method of any one of claims 11-153, wherein prior to the administration period is immediately prior to the administration period.

### Claim 155 (depends on 11, 153)

The method of any one of claims 11-153, wherein prior to the administration period is from about 1 day to about 14 days prior to the administration period.

### Claim 156 (depends on 11, 153)

The method of any one of claims 11-153, wherein prior to the administration period is from about 1 day to about 10 days prior to the administration period.

### Claim 157 (depends on 11, 153)

The method of any one of claims 11-153, wherein prior to the administration period is from about 1 day to about 7 days prior to the administration period.

### Claim 158 (depends on 11, 153)

The method of any one of claims 11-153, wherein prior to the administration period is from about 1 day to about 4 days prior to the administration period.
